Cellino Biotech, Inc.

Cellino is building the leading precision platform to scale personalized stem cell-based therapies, with the goal of unlocking regenerative medicine for hundreds of millions of patients.

Cellino’s proprietary platform combines label-free imaging and high-speed laser editing with machine learning to automate cell reprogramming, expansion, and differentiation in a closed cassette format, enabling potentially thousands of patient samples to be processed in parallel in a single facility.

Stem cell-derived regenerative medicines are poised to cure some of the toughest diseases within this decade, including Parkinson’s, diabetes, age-related macular degeneration and heart disease. Patient-specific cells potentially provide the safest, most effective cures for these indications. Cellino’s vision is to make personalized regenerative medicines viable at large scale.